News and Trends 8 Nov 2022
Telix Pharmaceuticals sees positive results in kidney cancer imaging study
Telix Pharmaceuticals Limited said it has highly positive top-line results from its pivotal phase III study of its investigational renal (kidney) cancer positron emission tomography (PET) imaging agent, TLX250-CDx (89…